MIMOSA Diagnostics

Toronto, Canada All Canada companies → — Founded 2016

Medical Device / Hardware Point-of-Care Diagnostics Specialty-Focused AI

Dermatology General Surgery Plastic Surgery Vascular Surgery

Dermatology AI Radiology & Imaging AI

Series A

Claim this company

Products

MIMOSA Imager

MIMOSA Diagnostics

Dermatology AI

MIMOSA Pro is an FDA-cleared, handheld AI imaging device that uses multispectral imaging to non-invasively assess tissue oximetry, temperature, and wound measurements, providing real-time insights for early intervention and improved patient outcomes across all skin tones.

See all 1 product →

About MIMOSA Diagnostics

MIMOSA Diagnostics is a healthcare AI company focused on developing non-invasive technology for the early detection of tissue damage, particularly foot ulcers in diabetic patients. Their flagship product, MIMOSA Pro, is a pocket-sized, handheld imaging device that utilizes near-infrared light to assess tissue health beneath the skin’s surface, making invisible injuries visible. This technology aims to provide clinicians with objective, quantifiable metrics for tissue oxygenation and temperature, enabling earlier interventions and proactive patient care across various settings, including hospitals, outpatient clinics, home care, and emergency situations.

The device captures images that are uploaded to a secure, HIPAA-compliant web portal, allowing healthcare professionals to remotely monitor patient progress, identify risks, and collaborate on treatment plans. MIMOSA Diagnostics’ approach emphasizes equitable healthcare by providing accessible diagnostic tools that are agnostic to skin pigment, clinical specialty, and care setting. The company’s mission is to revolutionize wound care and prevent severe complications like limb loss, which can be particularly prevalent in conditions like diabetes and peripheral vascular disease.

Focus Areas

tissue oximetry wound care pressure injury detection deep tissue injury detection remote patient monitoring multispectral imaging thermal imaging digital biomarkers equitable healthcare

Business Intelligence

Technology

cloud-native, AI-driven point-of-care insights, multispectral near-infrared spectroscopy (NIRS), infrared thermal imaging (LWIRT)

What Physicians Need to Know

Specialization in Wound Care

MIMOSA Diagnostics specializes in advanced wound care, including diabetic foot ulcers, burns, and post-operative surgical complications. Their technology helps clinicians assess tissue health to prevent severe outcomes like amputations.

Peripheral Vascular Disease (PVD)

The company focuses on early detection and management of peripheral vascular disease by providing insights into tissue perfusion and oxygenation, which are crucial for preventing complications.

Early Detection of Tissue Compromise

MIMOSA's core mission is the early detection of subsurface tissue damage before it becomes visible to the naked eye, enabling proactive intervention and improved patient outcomes.

Equitable Healthcare

MIMOSA Diagnostics is committed to equitable healthcare by providing a device that is skin pigment, clinical specialty, and care setting agnostic, ensuring access to critical health information for all patients, including those in remote areas or with darker skin tones.

Tissue Health Assessment

They offer comprehensive tissue health assessment through non-invasive imaging, measuring key biomarkers like tissue oxygenation, temperature, and providing high-dynamic range digital images.

Key Differentiator: Portability & Ease of Use

The MIMOSA Pro is a pocket-sized, handheld, and portable imaging device that can be easily used by any healthcare professional at the point-of-care, eliminating the need for large, expensive traditional scanning machines.

Key Differentiator: Non-invasive & Dye-free

The device is non-contact and does not require dyes or injected media to assess tissue health, making it safer and more convenient for patients.

Key Differentiator: Skin Pigmentation Agnostic

MIMOSA's algorithms are developed to account for skin melanin content, ensuring accurate imaging and assessment for all skin tones, addressing a limitation of other light-based optical technologies.

Technology Stack: Near-Infrared Light & Multispectral Imaging

The MIMOSA Pro utilizes near-infrared light and multispectral imaging to non-invasively assess tissue health by detecting subsurface physiological biomarkers.

Technology Stack: AI-Driven Insights

The platform incorporates AI to provide real-time point-of-care insights and is developing AI tools to predict patient outcomes and identify specific tissue health qualities for earlier intervention.

Technology Stack: Secure Cloud-Based Web Portal

Images and data captured by the MIMOSA Pro are uploaded to a secure, HIPAA-compliant web portal for remote clinician review, patient progress tracking, and team collaboration.

Technology Stack: Software-Based Updates

The device's diagnostics and support are largely software-based, allowing for overnight updates similar to a cell phone operating system, reducing the need for physical repairs.

Physician Tip

For physicians, MIMOSA Diagnostics offers a powerful, portable tool for proactive tissue intelligence. The MIMOSA Pro allows for early detection of tissue compromise, often before it's visible, which can significantly improve patient outcomes and potentially prevent severe complications like amputations. Its ease of use and portability make it suitable for various care settings, from hospitals to home care, and facilitates remote consultations with specialists. The objective, quantifiable metrics provided by the device, including tissue oxygenation and temperature, can help validate treatment efficacy, guide care plans, and support reimbursement documentation. Furthermore, its ability to function effectively across all skin tones promotes equitable care for a diverse patient population. The AI-driven insights can assist in risk profiling and identifying patients who require timely intervention.

The MIMOSA Pro integrates seamlessly into existing clinical workflows. Images and data are uploaded to a HIPAA-compliant web portal, enabling remote monitoring, collaboration among care teams, and tracking patient progress over time. The platform provides ready-to-export reimbursement documentation. While specific integrations with Electronic Health Records (EHR) systems are not explicitly detailed, the cloud-based portal and data accessibility suggest potential for such integrations to streamline patient data management and care coordination.

Products by MIMOSA Diagnostics

1 product in the directory

MIMOSA Imager

MIMOSA Diagnostics

Dermatology AI

What the Web Says

MIMOSA Diagnostics appears to be a company with a positive reputation among its employees, particularly regarding its product and company culture. The company develops a pocket-sized imaging device, MIMOSA Pro, which uses near-infrared light to assess tissue health and aims to provide inclusive and equitable healthcare. While there's limited information from dedicated product review sites like G2, Glassdoor, or Capterra specifically for MIMOSA Diagnostics' product, employee reviews on platforms like Indeed and SimplyHired offer insights into the company as an employer. There seems to be some confusion or conflation with other companies named 'Mosaic Diagnostics' or 'Mimosa' in general searches, which have different reviews, particularly on Reddit regarding diagnostic test accuracy.

Overall: Positive

Strengths

Great company culture and people
Fast-paced and challenging work environment, especially for students
Products promote inclusive and equitable healthcare
MIMOSA Pro offers real-time validation and helps adapt patient care plans proactively
Handheld, portable imaging device that is easy for healthcare professionals to use
Remote work opportunities and unlimited vacation

Limitations

Limited product reviews available on major platforms like G2, Glassdoor, or Capterra specific to MIMOSA Diagnostics' product.
Potential confusion with other companies named 'Mosaic Diagnostics' which have negative reviews regarding diagnostic test accuracy on Reddit.
Some general 'Mimosa' company reviews mention disorganization and financial stress, though these do not appear to be directly related to MIMOSA Diagnostics.

Based on reviews from: Indeed.com, SimplyHired.com, MIMOSA Diagnostics Website, Reddit

Last updated: 2026-10-18

Videos

News, demos, and interviews about MIMOSA Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for MIMOSA Diagnostics →

View all on YouTube

Press & Coverage

EIN Presswire

MIMOSA Diagnostics Wins Manulife and World Economic Forum UpLink's 'Shaping Canada's Longevity Advantage' Challenge

MIMOSA Diagnostics won the 'Shaping Canada's Longevity Advantage' Challenge, joining UpLink's global innovation ecosystem. The MIMOSA Pro is highlighted as the only FDA Class II and Health Canada approved, pocket-sized device for tissue oxygenation, thermography, wound measurement, and digital imaging.

2026-10

EIN Presswire

MIMOSA Diagnostics Wins Ontario Centre of Innovation's 2026 Mind2Market Award for MIMOSA Pro

MIMOSA Diagnostics received the Ontario Centre of Innovation's 2026 Mind2Market Award for its MIMOSA Pro device, recognizing the successful commercialization of research. The MIMOSA Pro helps clinicians identify early signs of pressure injuries and deep tissue injuries.

2026-10

Entrevestor

MIMOSA Raises Capital

MIMOSA Diagnostics closed a funding round led by Kern Venture Group, with participation from other investors, to accelerate market expansion and team building after launching its product in the US and gaining Health Canada approval.

2024-06

MIMOSA Diagnostics (Press Release)

MIMOSA Diagnostics Secures Convertible Debenture Financing to Accelerate Growth and US Commercialization

MIMOSA Diagnostics announced the successful closing of a convertible debenture financing round led by Archerwill Investments, the Ontario Centre for Innovation, Tidal Venture Partners, and the XDL Group, to expand operations and accelerate growth, particularly in the US.

2023-07

Entrevestor

MIMOSA CEO Cross Receives Toronto Star Nod

Dr. Karen Cross, CEO of MIMOSA Diagnostics, was recognized by The Toronto Star as one of fourteen Canadian entrepreneurs to watch. She co-founded MIMOSA in 2016, inspired by her grandfather's experience with a poorly healing injury.

2023-01

MIMOSA Diagnostics

International Pressure Injury Guideline Recognizes Thermographic Imaging and Tissue Oxygenation and Perfusion Monitoring as Advanced Technologies for Early Detection

MIMOSA Diagnostics highlights the recognition of thermographic imaging and tissue oxygenation/perfusion monitoring in international guidelines for early pressure injury detection, aligning with the MIMOSA Pro's capabilities.

unknown

Hamilton Health Sciences

HHS study shows promise for extra-early detection of pressure injuries

A study by Hamilton Health Sciences shows promise for extra-early detection of pressure injuries, featuring technology relevant to MIMOSA Diagnostics' focus on subsurface tissue health assessment.

unknown

MIMOSA Diagnostics

Testing technology to help diabetics avoid amputations

MIMOSA Diagnostics features an article on testing technology aimed at helping diabetic patients avoid amputations, underscoring the company's commitment to preventing severe complications from tissue injuries.

unknown

Frequently Asked Questions

What is MIMOSA Diagnostics' core product and how does it benefit wound care, peripheral vascular disease, diabetic foot ulcers, burns, and post-operative surgical complications?

MIMOSA Diagnostics' core product is the MIMOSA Pro, a handheld, pocket-sized imaging device that uses near-infrared and infrared light to non-invasively assess tissue health at the point-of-care. [2, 3, 20, 21] It provides insights into tissue oxygenation (blood flow), temperature (inflammation and infection), and wound measurements, which are crucial for early detection of tissue compromise in conditions like diabetic foot ulcers, peripheral vascular disease, burns, and post-operative complications. [15, 20, 21, 23] This technology helps clinicians make proactive decisions, potentially preventing severe complications like amputations and improving patient outcomes. [2, 10, 15, 17]

How does MIMOSA Diagnostics address equitable healthcare and the early detection of tissue compromise, especially in diverse patient populations?

MIMOSA Diagnostics is committed to driving equity in healthcare by providing tissue health imaging technology that is skin pigment, clinical specialty, and care setting agnostic. [2] The MIMOSA Pro can detect subsurface tissue damage before it's visible to the naked eye, which is particularly beneficial for patients with darker skin tones where traditional visual assessments may be less effective in identifying early signs of pressure injuries. [7, 15] This inclusive approach aims to ensure all patients, regardless of their location or skin color, have access to critical healthcare for early detection of tissue compromise. [2, 7, 8]

What is the regulatory and compliance status of MIMOSA Diagnostics' products?

The MIMOSA Pro has received Health Canada approval and is cleared by the FDA. [11, 12, 26] The company has a Manager of Quality & Regulatory Affairs to ensure compliance with regulatory standards. [19, 22]

Can you provide information on the pricing, reimbursement, and support for MIMOSA Diagnostics' products?

MIMOSA Diagnostics aims to make its technology affordable and accessible. [16] There is a reimbursement pathway for the use of the MIMOSA Pro for non-contact near-infrared spectroscopy studies of skin tissue, with specific CPT codes (0640T and 0859T) available. [24, 25] In the U.S., Medicare and Medicaid have acknowledged the MIMOSA Pro as an assessment tool for diabetic foot and venous leg ulcer treatment, allowing for reimbursement. [26] MIMOSA provides a secure cloud-based web portal with a billing tool to export necessary clinical documentation for reimbursement submissions. [3, 24] The company also offers resources like expert webinars, publications, case studies, and a learning platform for support. [2, 3, 14, 18]

What kind of partnerships and collaborations does MIMOSA Diagnostics engage in, and what is the company's stability?

MIMOSA Diagnostics has established partnerships with distribution companies like Venture Medical to expand its national footprint and increase access to its technology. [16] They also engage in clinical research partnerships, such as with Henson Shaving through MIMOSA Labs, to validate technologies. [5] The company has secured multiple funding rounds, including a Series A round in July 2023 and another funding round in June 2024, with investments from various groups, indicating ongoing growth and stability. [6, 9, 11, 12, 13] MIMOSA Diagnostics was founded in 2016 by Dr. Karen Cross and Dr. General Leung, and has a leadership team with experience in scaling health tech startups. [2, 6, 28]

Related Companies

Suggest an Edit → | Report an issue